- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05014594
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
The development of ascites is a landmark event in the natural history of cirrhosis and signifies a grim prognosis. Portal hypertension and splanchnic arterial vasodilatation are the major contributors in the development of ascites. Vasodilatation with the consequential decrease in effective circulating volume leads to the activation of sympathetic nervous system and renin angiotensin aldosterone system (RAAS), leading to antinatriuretic effects and retention of sodium and water. This results in the formation of ascites. Management of ascites primarily consists of salt restrictrion and diuretics. Liver transplant is the ultimate panacea.
Dapaglifozin, a Sodium glucose linked transporter-2(SGLT-2) inhibitor, is a part of the routine armamentarium for treatment of patients with Diabetes Mellitus type-2. Its safety is well established in non-diabetic patients too where it has been shown to improve cardiovascular outcomes. The risk of hypoglycemia is negligible as its action is independent of insulin. By virtue of its natriuretic effect, it has been shown to reduce hospitalisations in patients with heart failure irrespective of the presence of diabetes. We hypothesise that a similar natriuretic effect may help in suppressing the renin-angiotensin axis with improved mobilization of ascites in patients with cirrhosis. Pharmacokinetic data on the use of Dapaglifozin suggest that there is no need for dose modification in cirrhosis. The AUC and Cmax for Dapaglifozin in Child Pugh C cirrhosis is 67% and 40%, respectively. In a recent small case series, SGLT-2 inhibitors including dapaglifozin led to improvement in fluid retention and serum sodium, without acute kidney injury or encephalopathy, in patients with cirrhosis. However, SGLT-2 inhibitors have not been evaluated in randomized controlled trials. In this pilot study, we plan to evaluate the efficacy and safety of dapaglifozin in cirrhotics patients with recurrent ascites.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Virendra Singh, MD,DM,FASGE
- Phone Number: 0172-275-6338
- Email: virendrasingh100@hotmail.com
Study Contact Backup
- Name: Rishav Aggarwal, MBBS
- Phone Number: 9914032190
- Email: rishavaggarwal90@gmail.com
Study Locations
-
-
-
Chandigarh, India, 160012
- Recruiting
- Dept of Hepatology, PGIMER
-
Contact:
- Virendra Singh, MD, DM
- Phone Number: +911722756338
- Email: virendrasingh100@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-70 years
- Cirrhosis as determined by clinical findings, hemogram and liver function tests, endoscopic findings and imaging
- Recurrent ascites: Recurrent ascites will be defined as tense ascites recurring at least thrice within the last 1-year despite optimal standard medical treatment including large volume paracentesis and diuretics
Exclusion Criteria:
- Presence of chronic kidney disease as defined by an estimated glomerular filtration rate of <60 ml/min for more than 3 months. The MDRD-6 equation will be used for estimating GFR.
- Portal vein thrombosis
- Hepatocellular carcinoma.
- Gastrointestinal bleed in the preceding 2-weeks
- Overt hepatic encephalopathy in the preceding 1-month
- Documented hypoglycemia in the preceding 1-month
- Serum sodium < 125 meq/l
- History of skeletal fracture in the preceding year or any past history of fragility fracture
- History of peripheral vascular disease
- Acute kidney injury as defined by the International Club of Ascites criteria
- Infection within 1-month preceding the study
- Anatomic urologic defects that predispose to urinary tract infection
- Mixed ascites (additional etiology of ascites apart from portal hypertension)
- Any severe extra hepatic condition including respiratory and cardiac failure
- Acute-on-chronic liver failure as per the APASL or CANONIC criteria
- Treatment with drug with known effects on systemic and renal hemodynamics within 7 days of inclusion excepting beta-blockers
- Patients opting for liver transplant or TIPS
- Refusal to give consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A (Dapaglifozin)
Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
|
Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
|
Placebo Comparator: Group B (Placebo)
Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
|
Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care.
Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
control of ascites at 6-months
Time Frame: 6 months
|
Control of ascites will be defined as follows-
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in eGFR measured by MDRD-6 at 3 months and 6 months
Time Frame: 6 months
|
eGFR will be measured by MDRD-6 formula
|
6 months
|
Change in urine output at 2-weeks, 3-months and 6-months
Time Frame: 6-months
|
Change in 24-hour urine output (ml) at 6-months
|
6-months
|
Change in serum sodium (mEq/l) at 2-weeks, 3-months and 6 months
Time Frame: 6 months
|
Change in serum sodium (mEq/l)
|
6 months
|
Change in 24-hours urinary sodium (mEq) at 2 weeks, 3 months and 6 months
Time Frame: 6 months
|
Change in 24-hours urinary sodium (mEq)
|
6 months
|
Change in HbA1c at 3 and 6 months
Time Frame: 6 months
|
Change in HbA1c
|
6 months
|
Change in Child-Turcotte-Pugh (CTP) score at 3 months and 6 months
Time Frame: 6 months
|
Change in CTP score.
The CTP score incorporates the variables of serum bilirubin, albumin, prothrombin time-INR, grade of ascites and hepatic encephalopathy.
The score ranges from 5-15 and a higher score portends a worse prognosis
|
6 months
|
Change in model for end stage liver disease (MELD) score at 3 months and 6 months
Time Frame: 6 months
|
Change in MELD score.
The MELD score incorporates the variables of serum bilirubin, creatinine and Internation Normalised Ratio (INR).
Higher MELD score indicates worse prognosis
|
6 months
|
Incidence of spontaneous bacterial peritonitis (SBP), urinary tract infection (UTI) and other infections
Time Frame: 6 months
|
The diagnosis of SBP will be based on neutrophil count in ascitic fluid of >250/mm3 as determined by microscopy and positive ascitic fluid culture or >250 /mm3 with negative culture called as culture negative neutrocytic ascites.Other infections will be diagnosed as per CDC criteria.
|
6 months
|
Incidence of overt hepatic encephalopathy over 6-months
Time Frame: 6 months
|
Over hepatic encephalopathy (HE) will be defined as grade II or higher HE as per the West haven classification
|
6 months
|
Incidence of acute kidney injury over 6-months
Time Frame: 6 months
|
Acute kidney injury will be defined as per the International Club of Ascites criteria
|
6 months
|
Incidence of Hyponatremia (serum sodium <130 meq/L), hypokalemia (Serum potassium < 3.5 meq/L), hyperkalemia (Serum potassium >6meq/L) over 6-months.
Time Frame: 6 months
|
Hyponatremia: serum sodium <130 meq/L hypokalemia: serum potassium < 3.5 meq/L hyperkalemia: serum potassium >6meq/L)
|
6 months
|
Incidence of skeletal fractures over 6-months
Time Frame: 6 months
|
Incidence of skeletal fractures over 6-months
|
6 months
|
Change in bone densitometry as assessed by DEXA at 6-months
Time Frame: 6 months
|
Bone densitometry will be assessed by DEXA
|
6 months
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
Time Frame: 6 months
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
|
6 months
|
Incidence of hepatocellular carcinoma over 6-months
Time Frame: 6 months
|
Hepatocellular carcinoma will be diagnosed based on imaging findings and AFP
|
6 months
|
Changes in plasma renin activity and aldosterone levels at 6- months
Time Frame: 6 months
|
Changes in plasma renin activity (ng/ml/hr) and aldosterone (ng/dL) levels at 6- months
|
6 months
|
Frequency and volume of LVP over 6-months.
Time Frame: 6 months
|
Frequency and volume of ascitic fluid removed (in litres) over 6-months.
|
6 months
|
Survival at 6-months
Time Frame: Survival at 6-months
|
Survival at 6-months after start of therapy
|
Survival at 6-months
|
Safety of dapaglifozin as assessed by adverse effects
Time Frame: 6 months
|
Safety of dapaglifozin as assessed by adverse effects
|
6 months
|
Renal resistive index at 6 months
Time Frame: 6 months
|
Renal resistive index will be measured using ultrasound doppler interrogation of intrarenal arteries using formula (peak systolic velocity - end-diastolic velocity) / peak systolic velocity
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Dapa recurrent ascites
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
RenJi HospitalNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
Clinical Trials on Dapagliflozin (10Mg Tab) along with standard medical therapy
-
Hospital Israelita Albert EinsteinCompleted
-
The University of Hong KongNot yet recruitingChronic Kidney Diseases | Lupus NephritisHong Kong
-
University of PecsSuspended
-
Kirby InstituteNot yet recruiting
-
Qianfoshan HospitalRecruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaVilla Gaiato, Modena; Ospedale Regionale di LocarnoTerminated